Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REVVITY, INC.PKI · Entity 3382 | Director · Chairman and CEO | February 13, 2019 | February 15, 2019 |
| WEST PHARMACEUTICAL SERVICES INCWST · Entity 3201 | Director | May 04, 2026 | May 06, 2026 |
| Xylem Inc.XYL · Entity 430 | Director | May 14, 2026 | May 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REVVITY, INC.
Report date February 13, 2019 · Filed February 15, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 570,662 |
Reported balance
After 2019-02-13 transaction · row 1
1 source rowRow 1 · 2019-02-13 · Tax withholding · Disposed 16,889 · Balance 570,662 F1: These shares are being surrendered to satisfy a tax withholding obligation upon vesting of restricted stock originally granted on February 9, 2016, as required by the Reporting Person's Restricted Stock Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares are being surrendered to satisfy a tax withholding obligation upon vesting of restricted stock originally granted on February 9, 2016, as required by the Reporting Person's Restricted Stock Agreement.
WEST PHARMACEUTICAL SERVICES INC
Report date May 04, 2026 · Filed May 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,512.97 |
Reported balance
After 2026-05-04 transaction · row 1
1 source rowRow 1 · 2026-05-04 · Grant · Acquired 791 · Balance 5,512.97 F1: These shares of restricted stock units will vest in full on the date of the next annual shareholder meeting and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares of restricted stock units will vest in full on the date of the next annual shareholder meeting and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors.
Xylem Inc.
Report date May 14, 2026 · Filed May 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 38,706 |
Reported balance
After 2026-05-14 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-05-14 · Grant · Acquired 2,481 · Balance 38,706 F1: Reflects an award of restricted stock units pursuant to the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016) that are scheduled to vest in full on the trading day prior to the 2027 Annual Meeting of Shareholders. The Reporting Person has elected to defer the settlement of the RSU Award until Separation from Service. F2: Includes additional shares due to dividend reinvestment. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects an award of restricted stock units pursuant to the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016) that are scheduled to vest in full on the trading day prior to the 2027 Annual Meeting of Shareholders. The Reporting Person has elected to defer the settlement of the RSU Award until Separation from Service.
F2: Includes additional shares due to dividend reinvestment.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
NUVASIVE INC
Report date September 01, 2023 · Filed September 05, 2023
Section 16 reporting ended · disclosed 2023-09-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-09-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-09-01 · Disposition to issuer · Disposed 5,113 · Balance 0 F1: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F2: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-09-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-09-01 · Disposition to issuer · Disposed 850 · Balance 0 F1: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F2: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-09-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-09-01 · Disposition to issuer · Disposed 2,822 · Balance 0 F1: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F2: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-09-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-09-01 · Disposition to issuer · Disposed 2,130 · Balance 0 F1: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F2: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-09-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-09-01 · Disposition to issuer · Disposed 3,230 · Balance 0 F1: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F2: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-09-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-09-01 · Disposition to issuer · Disposed 2,577 · Balance 0 F1: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F2: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-09-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-09-01 · Disposition to issuer · Disposed 3,095 · Balance 0 F1: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F2: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-09-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2023-09-01 · Disposition to issuer · Disposed 2,702 · Balance 0 F1: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F2: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-09-01 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2023-09-01 · Disposition to issuer · Disposed 3,788 · Balance 0 F1: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F2: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-09-01 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2023-09-01 · Disposition to issuer · Disposed 4,816 · Balance 0 F1: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F2: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award. |
Filing footnotes · ownership attribution and instrument terms
F1: Represented a contingent right to receive one share of the Issuer's common stock upon vesting.
F2: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 10, 2017 Filed May 11, 2017 23:47 UTC | Xylem Inc. XYL · Entity 430 | GrantCommon Stock | 2,743 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-031666 · doc4.xml · nonDerivative · entry 1 FRIEL ROBERT F · CIK 0001224110 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,811 F1 · shares: Reflects the award of restricted stock units, which are scheduled to vest on the business day prior to the Xylem Inc. 2018 annual shareholder's meeting. F2 · balance_after: Additional shares also accrued through a qualified DRIP. Read SEC document |
| May 04, 2017 Filed May 5, 2017 20:05 UTC | REVVITY, INC. PKI · Entity 3382 | Exercise / conversionNQ Stock Option (right to buy) · Derivative | 25,100 | $0.00 Strike: $26.58 | $0.00 |
DisclosureSEC source: 0000899243-17-011975 · doc4.xml · derivative · entry 3 FRIEL ROBERT F · CIK 0001224110 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,100 shares Expires 2018-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option became exercisable in three equal annual installments beginning on February 8, 2012, which was the first anniversary of the date on which the option was granted. Read SEC document |
| May 04, 2017 Filed May 5, 2017 20:05 UTC | REVVITY, INC. PKI · Entity 3382 | SaleCommon Stock | 25,100 | $60.00 | $1,506,000.00 |
DisclosureSEC source: 0000899243-17-011975 · doc4.xml · nonDerivative · entry 2 FRIEL ROBERT F · CIK 0001224110 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 571,971 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by Mr. Friel on March 1, 2017. Read SEC document |
| May 04, 2017 Filed May 5, 2017 20:05 UTC | REVVITY, INC. PKI · Entity 3382 | Exercise / conversionCommon Stock | 25,100 | $26.58 | $667,158.00 |
DisclosureSEC source: 0000899243-17-011975 · doc4.xml · nonDerivative · entry 1 FRIEL ROBERT F · CIK 0001224110 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 597,071 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2017 Filed May 3, 2017 20:07 UTC | REVVITY, INC. PKI · Entity 3382 | Exercise / conversionNQ Stock Option (right to buy) · Derivative | 48,400 | $0.00 Strike: $26.58 | $0.00 |
DisclosureSEC source: 0000899243-17-011617 · doc4.xml · derivative · entry 3 FRIEL ROBERT F · CIK 0001224110 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,100 Underlying: Common Stock · 48,400 shares Expires 2018-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option became exercisable in three equal annual installments beginning on February 8, 2012, which was the first anniversary of the date on which the option was granted. Read SEC document |
| May 01, 2017 Filed May 3, 2017 20:07 UTC | REVVITY, INC. PKI · Entity 3382 | SaleCommon Stock | 48,400 | $60.01 | $2,904,484.00 |
DisclosureSEC source: 0000899243-17-011617 · doc4.xml · nonDerivative · entry 2 FRIEL ROBERT F · CIK 0001224110 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 571,971 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by Mr. Friel on March 1, 2017. F2 · price: The price reported represents a weighted average sale price of shares sold in multiple transactions at prices ranging from $60.00 to $60.02. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 01, 2017 Filed May 3, 2017 20:07 UTC | REVVITY, INC. PKI · Entity 3382 | Exercise / conversionCommon Stock | 48,400 | $26.58 | $1,286,472.00 |
DisclosureSEC source: 0000899243-17-011617 · doc4.xml · nonDerivative · entry 1 FRIEL ROBERT F · CIK 0001224110 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 620,371 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 27, 2017 Filed Apr 28, 2017 20:05 UTC | REVVITY, INC. PKI · Entity 3382 | Exercise / conversionNQ Stock Option (right to buy) · Derivative | 124,837 | $0.00 Strike: $26.58 | $0.00 |
DisclosureSEC source: 0000899243-17-011194 · doc4.xml · derivative · entry 3 FRIEL ROBERT F · CIK 0001224110 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,500 Underlying: Common Stock · 124,837 shares Expires 2018-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option became exercisable in three equal annual installments beginning on February 8, 2012, which was the first anniversary of the date on which the option was granted. Read SEC document |
| April 27, 2017 Filed Apr 28, 2017 20:05 UTC | REVVITY, INC. PKI · Entity 3382 | SaleCommon Stock | 124,837 | $60.11 | $7,503,952.07 |
DisclosureSEC source: 0000899243-17-011194 · doc4.xml · nonDerivative · entry 2 FRIEL ROBERT F · CIK 0001224110 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 571,973 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by Mr. Friel on March 1, 2017. F2 · price: The price reported represents a weighted average sale price of shares sold in multiple transactions at prices ranging from $60.01 to $60.28. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| April 27, 2017 Filed Apr 28, 2017 20:05 UTC | REVVITY, INC. PKI · Entity 3382 | Exercise / conversionCommon Stock | 124,837 | $26.58 | $3,318,167.46 |
DisclosureSEC source: 0000899243-17-011194 · doc4.xml · nonDerivative · entry 1 FRIEL ROBERT F · CIK 0001224110 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 696,810 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 07, 2017 Filed Feb 8, 2017 22:08 UTC | REVVITY, INC. PKI · Entity 3382 | GrantNQ Stock Option (right to buy) · Derivative | 115,221 | $0.00 Strike: $52.69 | $0.00 |
DisclosureSEC source: 0000899243-17-003129 · doc4.xml · derivative · entry 3 FRIEL ROBERT F · CIK 0001224110 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,221 Underlying: Common Stock · 115,221 shares Expires 2024-02-07 F3 · derivative.exercise_date: This option is scheduled to vest in three equal annual installments beginning on the first anniversary of the date of grant. Read SEC document |
| February 07, 2017 Filed Feb 8, 2017 22:08 UTC | REVVITY, INC. PKI · Entity 3382 | GrantCommon Stock | 25,223 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-003129 · doc4.xml · nonDerivative · entry 2 FRIEL ROBERT F · CIK 0001224110 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 571,973 F2 · shares: Shares are time-based restricted stock that are scheduled to fully vest on the third anniversary of the date of grant. Read SEC document |
| February 06, 2017 Filed Feb 8, 2017 22:08 UTC | REVVITY, INC. PKI · Entity 3382 | Tax withholdingCommon Stock | 15,781 | $52.17 | $823,294.77 |
DisclosureSEC source: 0000899243-17-003129 · doc4.xml · nonDerivative · entry 1 FRIEL ROBERT F · CIK 0001224110 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 546,750 F1 · shares: These shares are being surrendered to satisfy a tax withholding obligation upon vesting of restricted stock originally granted on February 4, 2014, as required by the Reporting Person's Restricted Stock Agreement. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.